Coronaviruses and other Novel Antiviral Targets
- 1st Edition, Volume 57 - November 17, 2021
- Imprint: Academic Press
- Editor: Katherine Seley-Radtke
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 1 5 1 1 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 1 5 1 2 - 0
Annual Reports in Medicinal Chemistry, Volume 57 in this long-running series, highlights new advances in the field with this new volume presenting interesting chapters on the Mecha… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAnnual Reports in Medicinal Chemistry, Volume 57 in this long-running series, highlights new advances in the field with this new volume presenting interesting chapters on the Mechanism of action of the broadly acting antiviral drug remdesivir, Improving properties of the nucleobase analogue T-706 as a potential anti-SARS-CoV-2 and anti-influenza compound, Antivirals for RNA virus infections Anno 2020-2021, Broad spectrum antiviral fleximer nucleosides, SARS-CoV-2 main protease inhibitors, The search for antivirals to treat alphavirus infections, Inhibitors of Ebola Virus targeting Innate immune evasion, Uracil derivatives as non-nucleoside inhibitors of viral infections, and more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Annual Reports in Medicinal Chemistry
- Updated release includes the latest information on the Coronaviruses and other novel antiviral targets
Undergraduates, graduates, academics, and researchers in the field of medicinal chemistry
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Improving properties of the nucleobase analogs T-705/T-1105 as potential antiviral
- Abstract
- 1: Introduction
- 2: T-705/T-1105 mechanism of action (MoA)
- 3: Chemical synthesis of the nucleoside of T-705 and T-1106 as well as their monophosphates
- 4: Cyclosaligenyl (cycloSal) nucleoside monophosphate prodrug approach
- 5: Nucleoside diphosphate prodrugs
- 6: Nucleoside triphosphate prodrugs
- 7: Conclusion
- References
- Chapter Two: Anno 2021: Which antivirals for the coming decade?
- Abstract
- 1: Introduction
- 2: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)
- 3: Influenza viruses
- 4: Respiratory syncytial virus (RSV)
- 5: Rhinoviruses
- 6: Ebolavirus (EBOV)
- 7: Human immunodeficiency virus (HIV)
- 8: Yellow fever virus (YFV)
- 9: Poliovirus (PV)
- 10: Hepatitis C virus (HCV)
- 11: Rabies virus (RABV)
- 12: Measles virus (MeV)
- 13: New coronaviruses (CoVs)
- 14: Conclusion
- References
- Chapter Three: Broad spectrum antiviral nucleosides—Our best hope for the future
- Abstract
- 1: Introduction
- 2: Early antiviral nucleosides—Obligate chain terminators
- 3: Acyclic obligate chain terminator nucleosides
- 4: Other obligate chain terminator antivirals
- 5: Antivirals that act by lethal mutagenesis
- 6: Newer antiviral therapeutics—And new mechanisms of action
- Acknowledgments
- References
- Chapter Four: The search for antivirals to treat alphavirus infections
- Abstract
- 1: Introduction
- 2: Current approaches in the discovery of novel anti-alphavirus compounds
- 3: Conclusions
- References
- Chapter Five: Inhibitors of Ebolavirus targeting innate immune evasion
- Abstract
- 1: Introduction
- 2: Interferon activation
- 3: Interferon signaling
- 4: VP35
- 5: VP24
- 6: EBOV inhibitors targeting innate immune evasion
- 7: Conclusions
- Acknowledgments
- References
- Chapter Six: Uracil derivatives as non-nucleoside inhibitors of viral infections
- Abstract
- 1: Introduction
- 2: 6-Substituted uracils derivatives
- 3: N1-Substituted uracil derivatives
- 4: 1,3-Disubstituted uracils
- 5: Nucleoside analogs as NNRTIs
- 6: Uracil derivatives with dual activity against HIV
- 7: Uracil derivatives as non-nucleoside inhibitors of various viruses
- 8: Dimers of NRTI and NNRTI
- 9: Conclusion
- Acknowledgment
- References
- Edition: 1
- Volume: 57
- Published: November 17, 2021
- No. of pages (Hardback): 254
- No. of pages (eBook): 254
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780323915113
- eBook ISBN: 9780323915120
KS
Katherine Seley-Radtke
Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to
nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic
emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently
used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as
the Program Director for UMBC’s Chemistry-Biology Interface graduate training program
funded by NIH since 2007. This program promotes hands on cross disciplinary research for
almost 50 PhD students from four departments at UMBC and UMB. She is currently the
Immediate Past President and Secretary-Elect for the International Society of Nucleosides,
Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral
Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections
and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy,
Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Affiliations and expertise
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USARead Coronaviruses and other Novel Antiviral Targets on ScienceDirect